Zhongguancun (000931.SZ): Marketing authorization application for edaravone dexborneol concentrated solution for injection accepted

Zhitong Finance APP News, Zhongguancun (000931.SZ) announced that its subsidiary Beijing Hualsu Pharmaceutical Co., Ltd. recently received a Notice of Acceptance issued by the National Medical Products Administration, and the marketing authorization application for Edaravone Dexborneol Concentrated Solution for Injection (specification: 5ml: Edaravone 10mg and Dexborneol 2.5mg) has been accepted. The drug is indicated for improving neurological symptoms, activities of daily living, and functional impairment caused by acute ischemic stroke.